...administered repeatedly without puncturing the lung. Oncorus has been developing the product based on the Seneca Valley virus...

...Biotherapeutics Inc. JX-594 Recombinant vaccinia virus (TK-deletion plus GM-CSF) Liver cancer Ph II Neotropix Inc. NTX-010...

...NTX-010 in 99 patients. Neotropix Inc. , Malvern, Pa. Product: Seneca Valley Virus ( NTX-010 ) (formerly SVV-001...

...administered. At the levels we are delivering, the main concern is clearly liver toxicity." Neotropix's NTX-010...

...modified to produce a toxic metabolite in tumor cells Brain cancer Phase I Neotropix Inc. NTX-010...

...designation for neuroendocrine cancers. Neotropix Inc. , Malvern, Pa. Product: Seneca Valley Virus ( NTX-010 ) (formerly SVV-001...

...FDA granted Orphan Drug designation for Neotropix's NTX-010 to treat neuroendocrine cancers. The naturally occurring oncolytic...
...testing for the indication. Neotropix Inc. , Malvern, Pa. Product: Seneca Valley Virus ( NTX-010 ) (formerly SVV-001...

...with various types of advanced neuroendocrine cancers. Neotropix Inc. , Malvern, Penn. Product: Seneca Valley Virus ( SVV-001...

...a series A round, enough to carry the company through Phase I/II trials of its SVV-001...

...Milestone Medica. The company said the financing should carry it through Phase I/II trials of SVV-001...